Adaptive Biotechnologies
Leveraging the adaptive immune system to diagnose and treat disease.
About
Adaptive Biotechnologies harnesses the adaptive immune system to power the Age of Immune Medicine, translating immune system genetics into actionable data. Their core offerings include clonoSEQ for Measurable Residual Disease assessment and an Immune Medicine Platform that informs clinical trials and the development of transformative medicines. They serve clinicians, biopharma companies, and patients by transforming how diseases are detected, monitored, and treated. Teams look it up for Biotech, HealthTech, Genomics.
Frequently asked
What does Adaptive Biotechnologies do?
Adaptive Biotechnologies is a Biotech company that offers Software | services | platform. Teams look it up for HealthTech, Genomics, Drug Discovery. It is based in Seattle, United States and was founded in 2009. Public records show $300M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Adaptive Biotechnologies raised?
Adaptive Biotechnologies has raised a total of $300M in funding. The most recent round on record is Series D.
Where is Adaptive Biotechnologies headquartered?
Adaptive Biotechnologies is headquartered in Seattle, United States.
When was Adaptive Biotechnologies founded?
Adaptive Biotechnologies was founded in 2009.
What industry does Adaptive Biotechnologies operate in?
Adaptive Biotechnologies operates in Biotech, HealthTech, Genomics, Drug Discovery, Clinical Trials.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.